Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Sep 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for patients with small cell lung cancer that has spread to the brain, known as brain metastases. The researchers want to find out if combining a medication called antirotinib hydrochloride with a type of radiation therapy called whole brain radiotherapy can be effective and safe for these patients.

To be eligible for this trial, participants need to have a confirmed diagnosis of small cell lung cancer and must have completed at least four cycles of initial chemotherapy. They should expect to live for more than three months and have no more than ten brain metastases. If patients meet these criteria, they may have the opportunity to take part in this study, which is currently active but not recruiting new participants. Those who join will receive the combined treatment and will be monitored for how well it works and any side effects. It's important for potential participants to know that certain health conditions or previous treatments may prevent them from joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria.
• • 2. The expected survival time is more than 3 months.
• • 3. Intracranial metastases ≤10.
• • 4. Adequate organ and bone marrow function.
• Exclusion Criteria:
• • 1. Patients who have used antiangiogenic drugs within the previous 1 month.
• • 2. Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer).
• • 3. Small cell lung cancer with hilar invasion or hemoptysis.
• • 4. Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage.
• • 5. An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment.
• • 6. Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications.
• • 7. Patients with life-threatening conditions of other severe and/or uncontrolled diseases.